DOSSIER · 13F-HR · Q2 2026

HSG Holding Ltd

$1.2B in tracked AUM across 26 positions as of Q2 2026.

HH
CIK 0001470766 · last filed Jun 30, 2026
Total AUM
$1.2B
as of Q2 2026
Holdings
26
positions
Whale Score
80
80
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026

HSG Holding's $1.89B Q4 2025 13F is no longer a balanced China internet basket — it is a concentrated China-platform and ADR portfolio built around one dominant thesis. PDD alone accounts for 63.6% of assets, with Boss Zhipin, Futu, Pony AI, and KE Holdings pushing the top five to more than 87% of the book. The quarter's most important change is the arrival of PDD as a new $1.20B position, which transformed the portfolio from a $373M small-cap ADR basket into a near-$1.9B concentrated platform wager. New positions in Pony AI, KE Holdings, Structure Therapeutics, and Circle widened the opportunity set, while Webull and 51Talk were cut sharply and Noah was sold outright. The whaleScore of 73.5 reflects the size of this concentrated ADR bet, not diversification.

The defining fact of this filing is simple: PDD is 63.6% of the book. At $1.20B and 11.35M shares, one position overwhelms every other line item. That means HSG is no longer expressing a broad view on Chinese ADRs; it is making a single, oversized wager on the continued strength of PDD's cross-border and domestic commerce ecosystem.

The New Top Five
Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
PDD
PDD HOLDINGS INC
$866M11.3M72.3%
02
FUTU
FUTU HLDGS LTD
$69M740K5.8%
03
PONY
PONY AI INC
$52M7.5M4.4%
04
CRCL
CIRCLE INTERNET GROUP INC
$42M669K3.5%
05
BEKE
KE HLDGS INC
$28M1.9M2.4%
06
GYRE
GYRE THERAPEUTICS INC
$25M3.8M2.1%
07
BZ
KANZHUN LIMITED
$24M1.9M2.0%
08
AVBP
ARRIVENT BIOPHARMA INC
$23M663K1.9%
09
DDL
DINGDONG CAYMAN LTD
$19M10.1M1.6%
10
GPCR
STRUCTURE THERAPEUTICS INC
$14M266K1.2%

Filing history

2026Q2Jun 30
$1.2B 36.7%
26 positionsView →
2025Q4Dec 31
$1.9B 406.7%
25 positionsView →
2025Q3Sep 30
$373M 80.8%
16 positionsView →
2025Q2Jun 30
$1.9B 777.9%
23 positionsLocked
2025Q1Mar 31
$221M 90.9%
15 positionsLocked
2024Q4Dec 31
$2.4B 6.3%
25 positionsLocked
2024Q3Sep 30
$2.6B 4.7%
26 positionsLocked
2024Q2Jun 30
$2.7B 150.8%
25 positionsLocked
2024Q1Mar 31
$1.1B 24.3%
26 positionsLocked
2023Q4Dec 31
$869M 6.8%
27 positionsLocked
2023Q3Sep 30
$933M 6.7%
28 positionsLocked
2023Q2Jun 30
$874M 8.1%
28 positionsLocked
Showing 12 of 48